文献速递慢性肾脏病

不同阶段CKD患者中Δ9-四氢大麻酚和大麻二酚的药代动力学及副作用

Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD.
PubMed 文献 · Kidney Int Rep · 2024-12-30

该非随机非盲临床研究比较了单剂Sativex(含5.4mg THC和5mg CBD)在CKD 4期和5期患者与健康志愿者中的药代动力学和副作用。结果显示CKD患者THC和CBD总暴露量更高,头晕副作用更明显,但个体间变异大,严重CKD患者使用大麻素需谨慎。

要点

  • CKD 4-5期患者THC和CBD暴露量显著高于健康对照。
  • CKD患者头晕评分在给药1.5小时后显著高于对照。
  • 严重CKD患者使用大麻素产品需谨慎,因个体变异大。

核心结论

  • CKD 4期和5期患者对THC、CBD及代谢物的总暴露量高于健康对照,副作用可能更明显,但个体间变异大,严重CKD患者使用大麻素需谨慎。

主要发现

  • THC的AUC中位数(四分位距)在对照、CKD 4期和5期分别为2.76(1.77-3.48)、4.16(3.35-5.28)和4.31(3.16-5.42)h×ng/ml,CKD患者与对照差异显著。
  • CBD及代谢物的AUC、Cmax和尿中代谢物排泄等药代动力学参数在CKD患者与对照间也显著不同。
  • 给药1.5小时后,各CKD组头晕NRS评分显著高于对照(平均NRS评分:0.7和1.5 vs. 0.1)。

关键数值与推荐

  • THC的AUC中位数(四分位距):对照2.76(1.77-3.48)h×ng/ml,CKD 4期4.16(3.35-5.28)h×ng/ml,CKD 5期4.31(3.16-5.42)h×ng/ml。
  • 给药1.5小时后头晕NRS平均评分:CKD 4期0.7,CKD 5期1.5,对照0.1。

临床怎么用

  • 严重CKD患者使用大麻素产品时应警惕暴露量增加和副作用增强,需个体化评估。

局限性

  • 研究为非随机非盲设计,个体间变异大,可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) affects approximately 10% of the global population and is associated with a large symptom burden. Medicinal cannabis is advised against in patients with severe CKD. However, pharmacokinetic and pharmacodynamic knowledge regarding their use in patients with CKD is lacking. METHODS: We aimed to investigate the pharmacokinetics and side effects of a single dose of Sativex, corresponding to 5.4 mg Δ9-tetrahydrocannabinol (THC) and 5 mg cannabidiol (CBD), in patients with CKD stages 4 and 5 compared with healthy volunteers (controls). The study was a nonrandomized and unblinded clinical study. RESULTS: Twenty controls and 29 patients with CKD completed the study. The area under the curve (AUC) for THC (median [interquartile range]) was 2.76 (1.77-3.48), 4.16 (3.35-5.28), and 4.31 (3.16-5.42) h × ng/ml for controls, and for patients with CKD stages 4 and 5, respectively, with significant differences between patients with CKD and controls. AUC for CBD and metabolites, and other pharmacokinetic parameters, such as maximum concentration (C max) and excretion of metabolites in urine were also significantly different between patients with CKD and controls. After 1.5 hours, numeric rating scale (NRS) scores for dizziness were significantly higher for each CKD group compared with controls (mean NRSscores: 0.7 and 1.5 vs. 0.1). CONCLUSION: Total exposure to THC, CBD, and metabolites was higher in patients with CKD stages 4 and 5 compared with controls, and side effects may be more pronounced; however, the intersubject variability was high. If cannabis products are administered to patients with severe CKD, caution is needed.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sønderskov MB, Khatir DS, Kjærgaard KD, et al. Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD. Kidney Int Rep. 2024. PMID: 40225360. doi:10.1016/j.ekir.2024.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。